Treatments being monitored by RAPID C-19

Treatments with CAS alerts

If there is evidence that a treatment being monitored by RAPID C-19 is effective against COVID 19, the MHRA may issue an alert to the healthcare system using the Central Alert System (CAS). This advises on the use of the treatment.

RAPID C-19 publishes the evidence that was available to the oversight group at this time as a summary briefing. Summary briefings are removed when an NHSE&I commissioning policy and NICE guidelines on the treatment are published.

See this information for budesonide:

Other treatments being monitored

  • acalabrutinib
  • ACE inhibitors (ramipril, lisinopril, perindopril, enalapril, trandolapril, captopril)
  • acetylcysteine
  • anakinra
  • androgen receptor antagonists (proxalutamide, enzalutamide and bicalutamide)
  • aspirin
  • AT-527 (plus ribavirin, enisamium and galidesivir)
  • aviptadil
  • AZD7442 (AZD8895 and AZD1061)
  • azithromycin
  • bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016)
  • baricitinib
  • BGB-DXP593, BGB-DXP604
  • BRII-196, BRII-198
  • budesonide
  • camostat and nafamostat
  • canakinumab
  • casirivimab and imdevimab (REGEN-COV)
  • CCR5 inhibitors (leronlimab, maraviroc, cenicriviroc)
  • CD24Fc
  • ciclesonide
  • ciclosporin
  • colchicine
  • convalescent plasma
  • dapagliflozin
  • dexamethasone (patients given rapid access)
  • dornase alfa
  • doxycycline
  • DZIF-10c
  • emtricitabine-tenofovir
  • favipiravir
  • GM-CSFs (otilimab, lenzilumab, mavrilimumab, namilumab, plonmarlimab [TJ003234])
  • heparin/enoxaparin sodium
  • human immunoglobulin
  • hydrocortisone (patients given rapid access)
  • hydroxychloroquine
  • imatinib and dasatinib
  • interferon beta-1a
  • interferon beta-1b
  • ivermectin
  • lopinavir/ritonavir
  • losartan
  • melatonin
  • mesenchymal stem cells therapy
  • methylprednisolone
  • molnupiravir
  • montelukast
  • niclosamide
  • nitazoxanide
  • nitric oxide
  • NSAIDs (ibuprofen, naproxen, celecoxib, indometacin, nimesulide)
  • oseltamivir
  • otilimab
  • P2Y12 inhibitor antiplatelet drugs (clopidogrel, prasugrel, ticagrelor)
  • povidone-iodine
  • prednisolone
  • pulmonary antifibrotics
  • ravulizumab
  • regdanvimab (CT-P59)
  • remdesivir (patients given rapid access)
  • rivaroxaban
  • ruxolitinib
  • sargramostim and molgramostim
  • sarilumab (patients given rapid access)
  • siltuximab
  • sofosbuvir-daclatasvir
  • sotrovimab (VIR-7831) and VIR-7832
  • SSRIs (fluvoxamine, fluoxetine)
  • statins (atorvastatin, rosuvastatin, simvastatin)
  • TNF inhibitors (adalimumab, infliximab, etanercept)
  • tocilizumab (patients given rapid access)
  • tofacitinib
  • vitamin C
  • vitamin D
  • zinc.

Read more about the treatments that patients have been given rapid access to in our rapid guideline on managing COVID-19.

This page was last reviewed on Thursday 23 September 2021.